Six-MicroRNA Prognostic Signature in Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma
Issued Date
2023-01-01
Resource Type
eISSN
24734284
Scopus ID
2-s2.0-85203211029
Pubmed ID
37163716
Journal Title
JCO Precision Oncology
Volume
7
Rights Holder(s)
SCOPUS
Bibliographic Citation
JCO Precision Oncology Vol.7 (2023)
Suggested Citation
Worakitchanon W., Panvongsa W., Siripoon T., Kitdumrongthum S., Wongpan A., Arsa L., Trachu N., Jinawath N., Chairoungdua A., Ngamphaiboon N. Six-MicroRNA Prognostic Signature in Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma. JCO Precision Oncology Vol.7 (2023). doi:10.1200/PO.23.00003 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/101962
Title
Six-MicroRNA Prognostic Signature in Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma
Author's Affiliation
Corresponding Author(s)
Other Contributor(s)
Abstract
PURPOSEMicroRNAs (miRNAs) have been evaluated as biomarkers in cancers. Therefore, we aimed to identify a prognostic miRNA signature from The Cancer Genome Atlas (TCGA) database and validate it in the Ramathibodi (RA) locally advanced head and neck squamous cell carcinoma (LA-HNSCC) cohort.METHODSThe correlation between candidate miRNAs and the survival of patients with LA-HNSCC in TCGA database was analyzed. A prognostic miRNA signature model was generated that classified patients into high-risk and low-risk groups. This candidate miRNA signature was further validated in the independent RA cohort using droplet-digital polymerase chain reaction.RESULTSIn TCGA database, we compared the expression of 277 miRNAs between 519 head and neck squamous cell carcinoma tissues and 44 normal tissues. The expression of hsa-miR-10b, hsa-miR-148b, hsa-miR-99a, hsa-miR-127, hsa-miR-370, and hsa-miR-500a was independently associated with overall survival (OS). Thus, we established the miRNA signature risk score from these six miRNAs and categorized patients into low-risk and high-risk groups. The median OS of TCGA patients was significantly shorter in the low-risk group than in the high-risk group (P <.001). The six-miRNA signature was further validated in the RA cohort (N = 87). The median OS of the low-risk group was significantly shorter compared with the high-risk group (P =.03). In multivariate analysis, the six-miRNA signature was an independent prognostic factor for OS in the RA cohort (HR, 1.958; 95% CI, 1.006 to 3.812; P =.048).CONCLUSIONWe identified a prognostic six-miRNA signature for patients with LA-HNSCC from TCGA cohort and validated it in our independent cohort. However, larger studies are warranted to confirm these results.